Risk and benefits of biologic therapy for inflammatory bowel diseases

Gut

Volumn 56, Issue 5, 2007, Pages 725-732

  D'Haens, Geert ^a  

^a IMELDA HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; AZATHIOPRINE PLUS MERCAPTOPURINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; FONTOLIZUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; ISONIAZID; MERCAPTOPURINE; METHOTREXATE; MLN 02; MONOCLONAL ANTIBODY CD28; NATALIZUMAB; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RIFAMPICIN; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; VISILIZUMAB; CYTOKINE;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ARTHRALGIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; BACTERIAL MENINGITIS; BIOLOGICAL THERAPY; CANCER; CANCER RISK; CLINICAL TRIAL; COLD INJURY; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; CYTOKINE RELEASE SYNDROME; DELAYED HYPERSENSITIVITY; DEMYELINATION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPLASIA; ENTERITIS; FOLLICULITIS; GRANULOMA ANNULARE; HEART FAILURE; HISTOPLASMOSIS; HUMAN; IMMUNOGENICITY; INFECTION; INFLUENZA; INJECTION SITE REACTION; INTESTINE CARCINOMA; LEUCOCYTOCLASTIC VASCULITIS; LICHENOID; LIVER FAILURE; LIVER FUNCTION; LUPUS LIKE SYNDROME; LYMPHOMA; MAINTENANCE THERAPY; MENINGOENCEPHALITIS; META ANALYSIS; MOTOR NEUROPATHY; MYCOBACTERIOSIS; NEUROLOGIC DISEASE; NONHUMAN; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PANCREATITIS; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; SKIN DEFECT; SYSTEMATIC REVIEW; T CELL LYMPHOMA; TOXOPLASMOSIS; TUBERCULOSIS; TUBERCULOUS PERITONITIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VASCULITIS; VIRUS ENCEPHALITIS; VIRUS HEPATITIS; VIRUS INFECTION; DRUG ERUPTION; FEMALE; METABOLISM; NEOPLASM; PREGNANCY COMPLICATION; REVIEW; RISK ASSESSMENT;

BIOLOGICAL THERAPY; CYTOKINES; DRUG ERUPTIONS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; OPPORTUNISTIC INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS; RISK ASSESSMENT;

EID: 34247504544     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.103564     Document Type: Article

References (51)

1. Blonski W, Lichtenstein GR. Complications of biological therapy for inflammatory bowel disease. Curr Opinion Gastroenterol 2006;22:30-43.
2. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8.
3. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355:1018-28.
4. Sackett DL. Bias in analytical research. J Chronic Dis 1979;32:51-63.
5. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30.
6. Toruner M, Loftus EV, Colombel JF, et al. Risk factors for opportunistic infections in inflammatory bowel diseases: a case-control study. Gastroenterology 2006;130:A71.
7. Sandborn WJ, Faubion WA. Biologies in inflammatory bowel disease: how much progress have we made ? Gut 2004;53:1366-73.
8. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
9. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
10. Rutgeerts P, van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593-610.
11. Matsumoto T, Tanaka T, Kawase I. Infliximab for rheumatoid arthritis in a patient with tuberculosis. N Engl J Med 2006;355:740-1.
12. Dheda K, Udwadia ZF, Huggett JF, et al. Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr Opin Pulm Med 2005;11:195-202.
13. Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med 2005;353:1530-1.
14. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81.
15. Yousry TA, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-33.
16. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25.
17. Rutgeerts P, Diamond RH, Bala M, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13.
18. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
19. Noman M, Vermeire S, Van Assche G, et al. The effectiveness of immunosuppression to suppress the formation of antibodies to infliximab in Crohn's disease. Gastroenterology 2004;126(Suppl):A54-5.
20. Von Assche G, Paintaud G, D'Haens G, et al. Continuation of immunosuppression is not required to maintain adequate infliximab efficacy in patients with Crohn's disease but may improve pharmacokinetics. Gastroenterology 2006;130(Suppl):A142.
21. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33.
22. Weinblatt ME, Keystone EC, Furst DE, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
23. Schreiber S, Khaliq-Kareemi M, Lawrance I, et al. Certolizumab pegol, a humanized anti-TNF pegylated Fab′ fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (precise). Gut 2005;37(Suppl):A82.
24. Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanised anti-interferon-gamma antibody, demonstrates safety and potential clinical adivily in patients with moderate-to-severe Crohn's disease. Gut 2006;55:1131-7.
25. 7 integrin. N Engl J Med 2005;352:2499-507.
26. Sandborn W, Feagan B, Stoinov S, et al. Certolizumab Pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled phase III study (precise 1). Gastroenterology 2006;130(Suppl):A107.
27. Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn's disease. N Engl J Med 2005;352:2193-201.
28. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069- 79.
29. Targan S, Salzberg B, Mayer L, et al. A phase 1 study: multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with intravenous steroids. Gastroenterology 2005;128(Suppl):A-75.
30. Hanauer S, Rutgeerts, P, D'Haens G, et al. Delayed hypersensitivity to infliximab (Remicade®) re-infusion after a 2-4 year interval without treatment. Gastroenterology 1999;116:A731.
31. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003;125:32-9.
32. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30.
33. Centocor. Hepatosplenic T-cell lymphoma in patients treated with Remicade® (infliximab) Press release May 16 2006.
34. Lémann M, Gérard de la Vallusière F, Bouhnik Y, et al. Intravenous cyclosporine for refractory attacks of Crohn's disease : long-term follow-up of patients. Gastroenterology 1998;114:G4178.
35. Mittal S, Milner B, Johnston P, et al. A case of hepatosplenic γ-δ T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur J Haematol 2006;76:531-4.
36. Navarro J, Ribera J, Mate J, et al. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 2003;44:531-3.
37. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
38. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080-7.
39. Siegel CA, Hur C, Korzenik J, et al. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1017-24.
40. Kane SV, Khatibi B, Reddy D. Use of immunosuppressant results in higher incidence of abnormal PAP smears in women with inflammatory bowel disease. Gastroenterology 2006;130(Suppl):A2.
41. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for indudion and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
42. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
43. Hommes D, Baert F, Van Assche G, et al. The ideal management of Crohn's disease: top down versus step up strategies, a randomized controlled trial. Gastroenterology 2006;130(Suppl):A108.
44. Tobon GJ, Canas C, Jaller JJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol, 2006[Epub ahead of print].
45. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-5.
46. Devos SA, Van Den Bossche N, De Vos M, et al. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003;206:388-90.
47. Kleyn CE, Griffiths CE. Infliximab for the treatment of psoriasis. Expert Opin Biol Ther 2006;6:797-805.
48. Sari I, Akar S, Birlik M, et al. Anti-tumor necrosis factor-alpha-induced psoriasis. J Rheumatol 2006;33:1411-14.
49. Chung ES, Packer M, Lo KH, et al. Anti-TNF therapy against congestive heart failure investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003;107:3133-40.
50. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99:2285-92.
51. Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005;21:733-8.